Notice of AGM and Report and Accounts

RNS Number : 9974T

Evocutis PLC

15 December 2011

 



Press Release

15 December 2011

Evocutis plc

("the Company")

Notice of AGM and Report and Accounts

Evocutis plc (AIM:EVO), the company focused on advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, today announces that copies of the Annual Report and Accounts for the year ended 31 July 2011 have been sent to shareholders along with the Notice of Annual General Meeting ("AGM"). Copies of both documents are also available from the Company's website, www.evocutis.com

The AGM will be held at the offices of IP Group plc, 24 Cornhill, London, EC3V 3ND on Tuesday, 24 January 2012 at 1pm.

- Ends -

For further information please contact Evocutis plc:

Evocutis plc
Dr Stephen Jones, Chief Executive Officer	Tel: [phone]
Tom Bannatyne, Chairman	www.evocutis.com

Nominated Advisor - Zeus Capital Ltd
Tom Rowley / Andrew Jones	Tel: [phone]
	www.zeuscapital.co.uk

Broker - XCAP Securities plc
Karen Kelly	Tel: [phone]
John Grant	www.xcapgroup.co.uk

Media enquiries:

Abchurch Communications
Sarah Hollins / Adam Michael / Jamie Hooper	Tel: [phone]
[e-mail]	www.abchurch-group.com

About Evocutis plc

With a rich portfolio of new product opportunities Evocutis offers antimicrobial and dermatological expertise to the cosmetic, consumer healthcare and pharmaceutical industries.

Being uniquely able to combine research for laboratory testing, advanced skin models and clinical testing, Evocutis offers an integrated service for the development of skin care products and ingredients. Through research and testing we enable our clients to advance the discovery of skin care products and validate claims of efficacy.

Evocutis works with companies at all stages of the product development pipeline offering R&D solutions from ownable technology platforms through to tailored research, and now provides an independent commercial testing facility to the pharmaceutical and healthcare industries. Unique characteristics of its colonised full thickness model of human skin (LabSkin^TM) allow rapid, cost effective screening of, for example, anti-aging, anti-inflammatory and antimicrobial ingredients and products for use on skin.

Offering high quality contract research services, Evocutis specialises in Human Skin Microbiology, tissue culture systems and Human Volunteer and Clinical Dermatology Research. When it comes to advanced laboratory and clinical evaluations of skincare products for the health and cosmetic markets, the Evocutis focus is simple: intelligent and specialised R&D input. 

For further information, please see www.evocutis.com.

 

END

 

 

MSCEAKALFFLFFFF